IGSF9

Across TCGA pan-cancer cohorts, IGSF9 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of IGSF9’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where IGSF9 RNA is repressed in tumor relative to normal tissue. In most cancer types IGSF9 is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

KIRC, BLCA, and HNSC are the cancer types where IGSF9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGSF9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.693	<.001	12	view →
BLCA	Male	III,IV	+3.512	<.001	11	view →
HNSC	Male	IV	+1.947	<.001	10	view →
LUSC	Female	All	+4.378	<.001	9	view →
LUAD	Female	III,IV	+3.033	<.001	9	view →
COAD	Female	II,III,IV	−1.564	<.001	9	view →
THCA	Male	III,IV	+1.098	<.001	9	view →
KIRP	Male	All	−0.879	<.001	9	view →
UCEC	All	All	+2.571	<.001	6	view →
BRCA	All	III,IV	+1.827	<.001	6	view →
READ	Male	All	−2.003	.006	4	view →
CHOL	All	II,III,IV	+2.210	.004	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

IGSF9–KIRC

Open the KIRC breakdown →